{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:07:48Z","timestamp":1788887268269,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T00:00:00Z","timestamp":1647734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T00:00:00Z","timestamp":1647734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["109-wf-swf-03"],"award-info":[{"award-number":["109-wf-swf-03"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["107-wf-swf-06"],"award-info":[{"award-number":["107-wf-swf-06"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"crossref","award":["EM110-PP-10"],"award-info":[{"award-number":["EM110-PP-10"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>\u00a0Chronic obstructive pulmonary disease (COPD) is a significant public health concern. The patients with acute exacerbations of COPD (AECOPD) and pneumonia have similar clinical presentations. The use of conventional diagnostic markers, such as complete blood count with differential and C-reactive protein (CRP), is the current mainstream method for differentiating clinically relevant pneumonia from other mimics. However, those conventional methods have suboptimal sensitivity and specificity for patients with a clinical suspicion of infection. The limitations often cause the ambiguity of the initiation of antibiotic treatment. Recently, our pilot study suggested that the patients with pneumonia have significantly higher plasma Sphingosine-1-phosphate (S1P) levels than controls. The initial findings suggest that plasma S1P is a potential biomarker for predicting prognosis in pneumonia. The aim of this study was to evaluate the value of S1P and CRP for discriminating COPD with pneumonia and AECOPD in an Emergency Department (ED) setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\u00a0Patients diagnosed with AECOPD or COPD with pneumonia were recruited from the Emergency Department of Wan Fang Hospital. The clinical data, demographics, and blood samples were collected upon ED admission. The concentration of plasma S1P was measured by ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>\u00a0Thirty-nine patients with AECOPD and 78 with COPD plus pneumonia were enrolled in this observational study. The levels of blood S1P and CRP were significantly higher in patients with COPD plus CAP compared to those in AE COPD patients. The area under the receiver operator characteristic (ROC) curve for the S1P and CRP for distinguishing between patients with COPD plus CAP and AECOPD is 0.939 (95% CI: 0.894\u20130.984) and 0.886 (95% CI: 0.826\u20130.945), whereas the combination of S1P and CRP yielded a value of 0.994 (95% CI: 0.897\u20131.000). By comparing with CRP or S1P, combining CRP and S1P had significantly higher AUC value for differentiating between the COPD with pneumonia group and the AECOPD group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that S1P is a potential diagnostic biomarker in distinguishing COPD with CAP from AECOPD. Additionally, the diagnostic ability of S1P can be improved when used in combination with CRP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-01991-1","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T16:02:19Z","timestamp":1647792139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sphingosine-1-phosphate and CRP as potential combination biomarkers in discrimination of COPD with community-acquired pneumonia and acute exacerbation of COPD"],"prefix":"10.1186","volume":"23","author":[{"given":"Chin-Wang","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Won","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Pin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer-Hwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Te","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shau-Ku","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-1182","authenticated-orcid":false,"given":"Shih-Chang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,20]]},"reference":[{"key":"1991_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD 2017 Report. 2017. http:\/\/goldcopd.org."},{"key":"1991_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","volume":"370","author":"JA Wedzicha","year":"2007","unstructured":"Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786\u201396.","journal-title":"Lancet"},{"key":"1991_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800353","author":"S Sethi","year":"2008","unstructured":"Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008. https:\/\/doi.org\/10.1056\/NEJMra0800353.","journal-title":"N Engl J Med"},{"key":"1991_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"key":"1991_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1378\/chest.11-2393","volume":"142","author":"ML Metersky","year":"2012","unstructured":"Metersky ML, Waterer G, Nsa W, Bratzler DW. Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest. 2012;142:476\u201381. https:\/\/doi.org\/10.1378\/chest.11-2393.","journal-title":"Chest"},{"key":"1991_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/thx.2005.041830","volume":"61","author":"DE O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax. 2006;61:354.","journal-title":"Thorax"},{"key":"1991_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.medmal.2014.01.002","volume":"44","author":"P Hausfater","year":"2014","unstructured":"Hausfater P. Biomarkers and infection in the emergency unit. Med Mal Infect. 2014;44:139\u201345.","journal-title":"Med Mal Infect"},{"key":"1991_CR8","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/cid\/cis1014","volume":"56","author":"SF Mitsuma","year":"2013","unstructured":"Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infect Dis. 2013;56:996\u20131002.","journal-title":"Clin Infect Dis"},{"key":"1991_CR9","unstructured":"Lindenauer PK, Shieh M-S, Stefan MS, Fisher KA, Haessler SD, Pekow PS, et al. Hospital procalcitonin testing and antibiotic treatment of patients admitted for COPD Exacerbation. Ann Am Thorac Soc. 2017. 201702\u2013133OC. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28795838. Accessed 2 Sep 2017."},{"key":"1991_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17512433.2017.1268051","volume":"10","author":"F Khan","year":"2017","unstructured":"Khan F, Owens MB, Restrepo M, Povoa P, Martin-Loeches I. Tools for outcome prediction in patients with community acquired pneumonia. Expert Rev Clin Pharmacol. 2017;10:201\u201311.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1991_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.ajem.2017.03.018","volume":"35","author":"M Bolatkale","year":"2017","unstructured":"Bolatkale M, Duger M, \u00dclfer G, Can \u00c7, Acara AC, Yi\u011fitba\u015f\u0131 T, et al. A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin. Am J Emerg Med. 2017;35:1121\u20135.","journal-title":"Am J Emerg Med"},{"key":"1991_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjmed.2007.10.033","volume":"121","author":"JD Chalmers","year":"2008","unstructured":"Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121:219\u201325.","journal-title":"Am J Med"},{"key":"1991_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1183\/09031936.03.00080203","volume":"21","author":"E Garc\u00eda V\u00e1zquez","year":"2003","unstructured":"Garc\u00eda V\u00e1zquez E, Mart\u00ednez JA, Mensa J, S\u00e1nchez F, Marcos MA, deRoux A, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J. 2003;21:702\u20135.","journal-title":"Eur Respir J"},{"key":"1991_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jinf.2016.01.002","volume":"72","author":"D Viasus","year":"2016","unstructured":"Viasus D, DelRio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J, Garavito A, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016;72:273\u201382.","journal-title":"J Infect"},{"key":"1991_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1586\/14787210.2013.825442","volume":"11","author":"D Viasus","year":"2013","unstructured":"Viasus D, Simonetti A, Garcia-Vidal C, Carratal\u00e0 J. Prediction of prognosis by markers in community-acquired pneumonia. Expert Rev Anti Infect Therapy. 2013;11:917\u201329. https:\/\/doi.org\/10.1586\/14787210.2013.825442.","journal-title":"Expert Rev Anti Infect Therapy"},{"key":"1991_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1139221","volume":"316","author":"R Pappu","year":"2007","unstructured":"Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295\u20138. https:\/\/doi.org\/10.1126\/science.1139221.","journal-title":"Science"},{"key":"1991_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nri2400","volume":"8","author":"J Rivera","year":"2008","unstructured":"Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753\u201363. https:\/\/doi.org\/10.1038\/nri2400.","journal-title":"Nat Rev Immunol"},{"key":"1991_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1476-5381.2011.01260.x","volume":"163","author":"M Schuchardt","year":"2011","unstructured":"Schuchardt M, T\u00f6lle M, Pr\u00fcfer J, van der Giet M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol. 2011;163:1140\u201362.","journal-title":"Br J Pharmacol"},{"key":"1991_CR19","first-page":"85","volume":"378","author":"Y Xiong","year":"2014","unstructured":"Xiong Y, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol. 2014;378:85\u2013105.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1991_CR20","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.4049\/jimmunol.0901019","volume":"183","author":"O Florey","year":"2009","unstructured":"Florey O, Haskard DO. Sphingosine 1-phosphate enhances Fc receptor-mediated neutrophil activation and recruitment under flow conditions. J Immunol. 2009;183:2330\u20136.","journal-title":"J Immunol"},{"key":"1991_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.prostaglandins.2012.07.003","volume":"104","author":"MZ Ratajczak","year":"2013","unstructured":"Ratajczak MZ, Borkowska S, Ratajczak J. An emerging link in stem cell mobilization between activation of the complement cascade and the chemotactic gradient of sphingosine-1-phosphate. Prostaglandins Other Lipid Mediat. 2013;104:122\u20139.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1991_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0216963","volume":"14","author":"SC Hsu","year":"2019","unstructured":"Hsu SC, Chang JH, Hsu YP, Bai KJ, Huang SK, Hsu CW. Circulating sphingosine-1-phosphate as a prognostic biomarker for community-acquired pneumonia. PLoS ONE. 2019;14:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0216963.","journal-title":"PLoS ONE"},{"key":"1991_CR23","doi-asserted-by":"crossref","unstructured":"Rule P, Identify TO, With LP, Pneumonia C-A, Fine MJ, Auble TE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243\u201350. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8995086.","DOI":"10.1056\/NEJM199701233360402"},{"key":"1991_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377\u201382.","journal-title":"Thorax"},{"key":"1991_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1089-0","author":"MS Winkler","year":"2015","unstructured":"Winkler MS, Nierhaus A, Holzmann M, Mudersbach E, Bauer A, Robbe L, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care. 2015. https:\/\/doi.org\/10.1186\/s13054-015-1089-0.","journal-title":"Crit Care"},{"key":"1991_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837.","journal-title":"Biometrics"},{"key":"1991_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5152\/TurkThoracJ.2020.19074","volume":"21","author":"Y Varol","year":"2020","unstructured":"Varol Y, Karakurt Z, \u00c7\u0131rak AKK, \u015eahin HDD, K\u0131rakl\u0131 C, K\u00f6m\u00fcrc\u00fco\u011flu B. Inappropriate utilization of antibiotics in COPD exacerbations. Turk Thorac J. 2020;21:397.","journal-title":"Turk Thorac J."},{"key":"1991_CR28","doi-asserted-by":"publisher","first-page":"00031","DOI":"10.1183\/23120541.00031-2019","volume":"5","author":"LJJ Finney","year":"2019","unstructured":"Finney LJJ, Padmanaban V, Todd S, Ahmed N, Elkin SL, Mallia P. Validity of the diagnosis of pneumonia in hospitalised patients with COPD. ERJ Open Res. 2019;5:00031\u20132019.","journal-title":"ERJ Open Res"},{"key":"1991_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1164\/rccm.200604-506OC","volume":"174","author":"JR Hurst","year":"2006","unstructured":"Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1991_CR30","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1378\/chest.09-2927","volume":"138","author":"JM Daniels","year":"2010","unstructured":"Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, Boersma WG. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138(5):1108\u201315. https:\/\/doi.org\/10.1378\/chest.09-2927.","journal-title":"Chest"},{"key":"1991_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1515\/jomb-2017-0011","volume":"36","author":"A \u00c7olak","year":"2017","unstructured":"\u00c7olak A, Yllmaz C, Toprak B, Akto\u01e7u S. Procalcitonin and CRP as biomarkers in discrimination of community-acquired pneumonia and exacerbation of COPD. J Med Biochem. 2017;36:122\u20136.","journal-title":"J Med Biochem."},{"key":"1991_CR32","doi-asserted-by":"publisher","first-page":"147997231876976","DOI":"10.1177\/1479972318769762","volume":"16","author":"E Titova","year":"2018","unstructured":"Titova E, Christensen A, Henriksen AH, Steinshamn S, \u00c5sberg A. Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: a prospective observational study. Chronic Respir Dis. 2018;16:147997231876976. https:\/\/doi.org\/10.1177\/1479972318769762.","journal-title":"Chronic Respir Dis"},{"key":"1991_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jbior.2016.09.007","volume":"63","author":"DL Ebenezer","year":"2017","unstructured":"Ebenezer DL, Fu P, Suryadevara V, Zhao Y, Natarajan V. Epigenetic regulation of pro-inflammatory cytokine secretion by sphingosine 1-phosphate (S1P) in acute lung injury: role of S1P lyase. Adv Biol Regul. 2017;63:156\u201366. https:\/\/doi.org\/10.1016\/j.jbior.2016.09.007.","journal-title":"Adv Biol Regul."},{"key":"1991_CR34","doi-asserted-by":"publisher","first-page":"L603","DOI":"10.1152\/ajplung.90357.2008","volume":"296","author":"R Wadgaonkar","year":"2009","unstructured":"Wadgaonkar R, Patel V, Grinkina N, Romano C, Liu J, Zhao Y, et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol. 2009;296:L603\u201313. https:\/\/doi.org\/10.1152\/ajplung.90357.2008.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"1991_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/SHK.0000000000001376","volume":"53","author":"A Feng","year":"2020","unstructured":"Feng A, Rice AD, Zhang Y, Kelly GT, Zhou T, Wang T. S1PR1-associated molecular signature predicts survival in patients with sepsis. Shock. 2020;53(3):284\u201392. https:\/\/doi.org\/10.1097\/SHK.0000000000001376.","journal-title":"Shock"},{"issue":"3","key":"1991_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/15412555.2016.1266317","volume":"14","author":"A Pizzini","year":"2017","unstructured":"Pizzini A, Lunger F, Sahanic A, Nemati N, Fuchs D, Weiss G, Kurz K, Bellmann-Weiler R. Diagnostic and prognostic value of inflammatory parameters including neopterin in the setting of pneumonia, COPD, and acute exacerbations. COPD J Chronic Obstr Pulm Dis. 2017;14(3):298\u2013303. https:\/\/doi.org\/10.1080\/15412555.2016.1266317.","journal-title":"COPD J Chronic Obstr Pulm Dis"},{"key":"1991_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57108-0","author":"W Bertrams","year":"2020","unstructured":"Bertrams W, Griss K, Han M, Seidel K, Klemmer A, Sittka-Stark A, Hippenstiel S, Suttorp N, Finkernagel F, Wilhelm J, Greulich T, Vogelmeier CF, Vera J, Schmeck B. Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-019-57108-0.","journal-title":"Sci Rep"},{"key":"1991_CR38","first-page":"325","volume":"221","author":"AL Jung","year":"2020","unstructured":"Jung AL, J\u00f8rgensen MM, B\u00e6k R, Griss K, Han M, Brinke KAD, et al. Surface proteome of plasma extracellular vesicles as biomarkers for pneumonia and acute exacerbation of chronic obstructive pulmonary disease. J Infect Dis J Infect Dis. 2020;221:325\u201335.","journal-title":"J Infect Dis. J Infect Dis"},{"key":"1991_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2015","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR, Andreu Z, Zavec AB, Borr\u00e0s FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell vesicles. 2015;4:1\u201360.","journal-title":"J Extracell vesicles."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-01991-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T16:03:43Z","timestamp":1647792223000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-01991-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,20]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-01991-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,20]]},"assertion":[{"value":"10 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Association of Taipei Medical University Joint Institutional Review Board (TMU-JIRB NO: N201602089).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}